Hansa Medical, a biopharmaceutical company developing novel immunomodulatory enzymes, today announced that the board of directors have appointed Søren Tulstrup as new President and CEO. Hansa Medical’s acting CEO Ulf Wiinberg reverts to his former role as Chairman of Hansa Medical and Birgit Stattin Norinder reverts to her former role as member of the board of directors.
Søren has a broad and extensive background as senior executive in the global biopharma industry. Recently, he served as CEO of Vifor Pharma AG, a Glattbrugg, Switzerland-based global pharmaceutical company with a market-leading position within chronic kidney disease, annual sales of approximately USD 1 billion and 2,000 employees.
